Uncovering the Newest Research in Antiviral-Drugs Development and Potential of Combined Therapy
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".
Deadline for manuscript submissions: 10 September 2024 | Viewed by 4766
Special Issue Editor
Interests: drug metabolism; drug delivery; drug safety; nuclear receptor biology; anti-infective and anticancer agents; hepatotoxicity; nanotechnology; oncological signaling
Special Issue Information
Dear Colleagues,
Emerging viral diseases, exemplified by the current COVID-19 pandemic, cause global disruptions to public health, financial systems, and even social stability. The continuous evolution of many viral pathogens, particularly surface antigens, contribute to waning immunity and the failure of existing immunotherapy. Another challenge is high co-infection rates among various types of viruses, complicating clinical management. There is an urgent need to identify new antiviral drugs and develop novel therapeutic strategies for mono- and co-infections. This Special Issue is a collection of articles on the latest research in antiviral-drug design, delivery, and potential of combined use for synergy.
Dr. Bingfang Yan
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- virus
- mono- and co-infection
- pandemic
- anti-viral drugs
- design
- delivery
- safety
- combined therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.